GlassScriptPhysician profile
Jagga Alluri
NPI 1053360008
$64,135.84
in general payments reported to CMS, 2019-2025
65 companies · $8,622 in 2025
The $8,622 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,611 · 2020: $3,966 · 2021: $8,386 · 2022: $12K · 2023: $18K · 2024: $9,942 · 2025: $8,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $15K · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,500.00 |
| Food and Beverage | $14,652.91 |
| Education | $116.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,212.35 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $3,407.36 | 2019-2022 | |
| Ucb, INC. | $1,688.94 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Eisai INC. | $1,681.06 | 2019-2024 | |
| Biogen, INC. | $1,374.30 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Neurelis, INC. | $1,327.64 | 2020-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $1,267.14 | 2019-2024 | Austedo Xr, Austedo |
| Scilex Pharmaceuticals INC. | $1,094.81 | 2021-2025 | Ztlido |
| Pfizer INC. | $1,071.69 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $961.48 | 2019-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $901.14 | 2021-2025 | Xcopri |
| Genzyme Corporation | $800.56 | 2019-2023 | |
| Amgen INC. | $790.92 | 2019-2025 | Uplizna, Aimovig |
| Argenx US, INC. | $789.56 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $771.13 | 2019-2024 | Amyvid, Kisunla, Emgality |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagga Alluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.